ENDRA Life Sciences Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ENDRA Life Sciences Inc. on February 5, 2018, covering events occurring on January 30, 2018. The Company is an emerging growth company incorporated in Delaware, focused on life sciences technologies.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a material definitive agreement.
Material Changes
- Agreement Extension: On January 30, 2018, the Company entered into Amendment 2 to its Collaborative Research Agreement with General Electric Company (GE).
- Term Extension: The Amendment extends the term of the original agreement (dated April 22, 2016) to January 22, 2020.
Guidance, Outlook, and Risks
The filing includes a Regulation FD disclosure referencing a press release issued on February 5, 2018, regarding the agreement. The text does not provide specific financial guidance, management commentary on future performance, or detailed risk factors beyond the standard incorporation of the agreement text by reference.
Key Facts for Investor Verification
- Verify the specific financial terms and obligations within Amendment 2 to the GE Collaborative Research Agreement (Exhibit 10.1).
- Confirm the strategic impact of extending the partnership with GE through January 2020 on the Company's product development timeline.
- Review the press release (Exhibit 99.1) for additional context not included in the 8-K summary text.